Covid-19 vaccine: Supplying Covaxin at Rs 150/dose to Centre ‘not sustainable’ in long run, says Bharat Biotech

[ad_1]


Talking about the higher pricing of Covaxin for private sector players, the company said this is purely due to fundamental business reasons.

[ad_2]

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Polynion

Binance Prediction

Metamask

papamiaspizza.com